Topiramate

Topamax, Qudexy XR and Eprontia: initial monotherapy for partial-onset or primary generalized tonic-clonic seizures age ≥2; adjunctive treatment of those seizures and Lennox-Gastaut seizures age ≥2. Trokendi XR uses the same seizure categories at age ≥6. All four prevent migraine at age ≥12.

Choice depends on seizure type, concomitant medicines, renal function, reproductive risk and ability to use the formulation. This U.S. standalone-topiramate reference does not supply dosing for off-label psychiatric/weight indications, phentermine/topiramate combinations or acute migraine rescue. Current manufacturer records are used rather than older repackager labels.

IR means Topamax/Eprontia; XR means the exact Qudexy or Trokendi product. These targets require individualized titration and organ-function review.

Monotherapy age 2–9 for Topamax/Eprontia/Qudexy or 6–9 for Trokendi: start 25 mg nightly in week one, then 50 mg/day in week two if tolerated; increase total by 25–50 mg weekly, attempting minimum maintenance over 5–7 weeks. IR divides into two doses; XR is once daily. Weight-based monotherapy targets below are total daily mg, not mg/kg.

All selected products may be taken without regard to meals. Do not assume two XR products have the same opening instructions.

Missed-dose instructions differ: Topamax/Eprontia take a single missed dose when remembered unless the next is within six hours, then skip; never double. Topamax and Eprontia Medication Guides advise contacting the clinician after more than one missed dose; Eprontia counseling text also advises contact after a missed dose. Qudexy says take a single missed dose as soon as possible and contact after multiple misses. Trokendi directs patients to ask their clinician for missed-dose instructions; do not impose the IR six-hour rule on it.

CrCl <70 mL/min/1.73 m²: selected labels recommend half the usual adult dose. Hemodialysis can remove substantial drug; a supplemental dose may be needed according to dialysis duration/system and residual clearance, without a universal supplement. Hepatic dysfunction can reduce clearance but has no fixed adjustment algorithm. Withdraw gradually for any indication to reduce seizure risk; medically necessary rapid withdrawal requires monitoring.

Current selected labels contraindicate prior hypersensitivity to topiramate, the exact product or its inactive ingredients, including reported anaphylaxis or angioedema. Trokendi XR additionally contraindicates alcohol within six hours before or after administration. Reproductive risk is a serious U.S. warning; do not misrepresent a different jurisdiction’s pregnancy-prevention restrictions as this U.S. label’s formal contraindication list.

No boxed warning appears in these selected current U.S. labels. Serious eye, metabolic, fetal, psychiatric, skin/allergic and other warnings still apply; absence of a box does not reduce the need for monitoring.

Paresthesia, appetite/weight loss, taste change, dizziness, fatigue/somnolence, memory/concentration/language effects and gastrointestinal symptoms are reported; rates depend on dose, indication, age and formulation and should not be pooled. Postmarketing reports include serious hepatic, skin and ocular events. Overdose can cause seizures, coma, hypotension and severe acidosis: stop excess dosing and seek urgent supportive/toxicology care (U.S. Poison Help 1-800-222-1222). Hemodialysis removes topiramate effectively.

Registry data link fetal exposure to oral clefts/other major malformations and small-for-gestational-age birth. Consider alternatives before conception and reassess benefit/risk promptly if pregnant, particularly for non-life-threatening indications. Use effective contraception and address the drug interaction. Monitor maternal and exposed newborn acidosis; pregnancy registry enrollment is encouraged. Topiramate enters milk; infant diarrhea/somnolence are reported and milk-production effects are unknown. Balance maternal need and breastfeeding benefit with infant monitoring.

Epilepsy minimum ages: Topamax/Eprontia/Qudexy ≥2, Trokendi ≥6. Migraine prevention ≥12 across selected products. Follow weight-based seizure regimens and growth/weight, bicarbonate, heat tolerance, cognition and bone-health monitoring. Younger-age studies do not expand approval. Older adults may need adjustment because renal function is reduced; limited geriatric trial data do not establish equivalence in every setting.

Reduced kidney function lowers clearance: use half the usual adult dose below CrCl 70 and individualize dialysis supplementation. Liver impairment reduced clearance (~26% in a studied moderate/severe population); monitor/titrate cautiously without inventing a numerical hepatic reduction. These adult recommendations are not a complete pediatric organ-failure algorithm.

The precise clinical mechanisms are not fully established. Preclinical findings include voltage-dependent sodium-channel blockade, enhancement of selected GABA-A responses, AMPA/kainate glutamate antagonism and carbonic-anhydrase inhibition.

Immediate-release

Topamax peak ~2 hours after a studied 400 mg dose; mean half-life ~21 hours; steady state ~4 days with normal kidney function.

Extended-release

Qudexy single-dose peak ~20 hours, effective half-life ~56 hours; Trokendi single-dose peak ~24 hours and repeat-dose elimination half-life ~31 hours. Different study definitions/formulations prevent treating these as one duration.

Elimination

Not extensively metabolized; ~70% eliminated unchanged in urine. Kidney dysfunction and enzyme-inducing seizure medicines alter exposure.

Formulation comparison

Topamax sprinkles/tablets are bioequivalent per its label; selected XR labels compare once-daily exposure with twice-daily IR. Switching remains product-specific and supervised.

Track seizures or migraine days and functional benefit, renal function and baseline/periodic bicarbonate. Review cognition, mood/suicidality, vision, sweating/temperature, appetite/weight and pediatric growth/bone risks. Measure ammonia with unexplained lethargy/vomiting/mental change or hypothermia, especially with valproate. Review pregnancy plans/contraception and interacting medicines. With Qudexy, assess cardiac history and new syncope/palpitations or conduction concerns.

Do not abruptly stop or change release forms. Avoid driving until cognitive and sedative effects are understood. Maintain appropriate hydration and watch overheating. Acute eye symptoms, severe rash/blistering, fever with swelling, airway swelling, serious mental changes or suicidal thoughts need urgent/emergency assessment. Review missed-dose instructions for the dispensed product and contact the clinician after multiple missed doses; do not double. Follow calibrated solution measuring and product-specific sprinkle/intact rules.

Topamax immediate-release tablets are the representative product; the selected label also covers sprinkles. Exact pill/capsule appearance differs for generics; verify pharmacy packaging. This profile is not an exhaustive generic/repackager or international formulation inventory.

Topamax tablets: tightly closed at 15–30°C; sprinkles: tightly closed at or below 25°C; protect both from moisture. Qudexy XR: tightly closed at 20–25°C, excursions 15–30°C, moisture protection. Trokendi XR: well closed at 25°C, excursions 15–30°C; protect from moisture/light. Eprontia: 20–25°C, excursions 15–30°C; discard unused solution 90 days after first opening. Sprinkle mixtures must be consumed immediately.